The numbers may be too small to allow any firm conclusions to be drawn, but Clavis Pharma ASA reported positive Phase II data for a combination of elacytarabine and idarubicin in patients with early stage acute myeloid leukemia (AML) who had either relapsed on or proved refractory to a first-line therapy that included cytarabine. Read More

LONDON – Scientists have tracked the cause of a rare genetic condition that causes muscular weakness to a mutation affecting neurotransmission. Read More

LONDON – Scientists at the Institute of Cancer Research (ICR) in London published Tuesday details of the Phase III trial of Johnson & Johnson's prostate cancer drug Zytiga (abiraterone acetate) in men who had not received chemotherapy, a day after the FDA agreed to a label extension allowing the drug to be used at that earlier stage of the disease. Read More

LONDON – The British government announced a £100 million (US$161 million) plan to make the UK the first country in the world to introduce whole-genome sequencing into a mainstream health care system. Read More

Biotie Therapies Oyj got a final-quarter lift from its Parkinson's disease drug tozadenant (SYN115), which hit the primary endpoint of a Phase IIb trial in 420 patients. Read More

BRISTOL, UK – The 25 clinical trials of cell therapies that are in progress currently in the UK could represent the foundations of £10 billion (US$16.1 billion) industry. Read More

• Genmab A/S, of Copenhagen, Denmark, will collaborate with Kyowa Hakko Kirin Co. Ltd., of Tokyo, to develop bispecific antibodies based on Genmab's DuoBody platform. Read More